ICCM
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/E is N/A; Graham Number cannot be calculated due to lack of earnings.
- Low absolute share price
- High Price/Sales ratio (7.77) for a non-profitable entity
- Price/Book of 2.61 is high given the negative ROE
Growth is present in revenue but not yet translating to the bottom line.
- Consistent revenue growth (46% YoY and Q/Q)
- Aggressive analyst price targets
- Earnings progression remains negative
- High cash burn implied by operating margins
Historical price trend is overwhelmingly bearish.
- 5-year return of -97%
- 1-month return of -51.7%
Balance sheet is clean, but operational health is poor.
- Low Debt/Equity (0.02)
- Strong Current Ratio (2.61)
- Piotroski F-Score of 4/9 is only marginally stable
- Negative ROA and ROE
Company is in a growth/burn phase; dividends are not applicable.
- No dividend history
- Zero payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ICCM and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ICCM
IceCure Medical Ltd
Primary
|
-97.0% | -71.2% | -71.9% | -62.9% | -51.7% | +7.7% |
|
DARE
Daré Bioscience, Inc.
Peer
|
-91.0% | -85.0% | -38.6% | -21.2% | +15.7% | -2.8% |
|
AYTU
Aytu BioPharma, Inc.
Peer
|
-98.4% | -24.2% | +61.7% | +2.7% | +6.7% | +1.5% |
|
BTAI
BioXcel Therapeutics, Inc.
Peer
|
-99.8% | -99.6% | -30.1% | -56.4% | -37.0% | -18.7% |
|
EKSO
Ekso Bionics Holdings, Inc.
Peer
|
-91.1% | -64.0% | +54.0% | +66.6% | -27.2% | -18.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ICCM
IceCure Medical Ltd
|
BEARISH | $26.25M | - | -188.8% | -% | $0.32 | |
|
DARE
Daré Bioscience, Inc.
|
BEARISH | $25.77M | - | -% | -% | $1.77 | Compare |
|
AYTU
Aytu BioPharma, Inc.
|
NEUTRAL | $27.51M | - | -50.2% | -20.5% | $2.7 | Compare |
|
BTAI
BioXcel Therapeutics, Inc.
|
BEARISH | $29.51M | - | -% | -% | $1.09 | Compare |
|
EKSO
Ekso Bionics Holdings, Inc.
|
BEARISH | $31.11M | - | -107.6% | -91.4% | $8.73 | Compare |
Past News Coverage
Recent headlines mentioning ICCM from our newsroom.